MUMBAI -India's Sun Pharmaceutical Industries Ltd. (524715.BY) said Thursday its unit has received a tentative approval from the U.S. Food and Drug Administration to sell generic uroxatral tablets.
Sun Pharmaceutical will sell uroxatral, a copycat of Sanofi-Aventis SA's (SAN.FR) Uroxatral extended release tablets, in doses of 10 milligram, the company said in a statement to the Bombay Stock Exchange.
Uroxatral is used to treat benign prostatic hyperplasia, commonly known as enlarged prostate.
No comments:
Post a Comment